Candidiasis, Septic Shock
Conditions
Keywords
Septic shock, Candidiasis, Candidemia, Bacteremia, Immunoparalysis
Brief summary
Septic shock is associated with acquired immunoparalysis which is associated with a high risk of nosocomial acquired infection. Nosocomial candidiasis is associated with a 50% rate of mortality but is difficult to diagnose. The use of colonization indexes and risk factors on the other hand expose to unnecessary use of antifungals. The aim of the present study is to evaluate whether the host response to infection associated with candida biomarkers would help to anticipate the candidiasis onset.
Detailed description
Single center prospective observationnal study. Inclusion: all consecutive patients subsequently to a septic shock with no Candida infection. Measured parameters: host response (HLADR, CD64, inflammatory cytokines consecutive to LPS exposition) and Candida biomarkers (beta D Glucan, Mannan Ag and Ig), demographics, outcome (occurence of Candida nosocomial infection, morbidity and survival)
Interventions
DIAGNOSTIC_TESTCandidiasis infection occurence
Candidiasis infection occurence
Sponsors
University Hospital, Montpellier
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Age \> = 18 years * The patients in toxic shock defined according to the Bone criteria * Informed consent of the patient or his reliable person (poursuit consent in this case). Possibility of inclusion according to the emergency procedure with the obligation of research for the consent with the reliable person and with the patient. * Obligation of membership or beneficiary to have a national insurance
Exclusion criteria
* Pregnant or breast-feeding women according to the article L1121-5 of the CSP * Vulnerable people according to the article L1121-6 of the CSP 9358 \_ * Neutropénie 500 / mm3 * Infection by the HIV, the hepatitis C or B active column * Biotherapics (anti-CD20, anti-TNFa, anti-IL-6) * Treatments immunosuppresseurs (methotrexate, azathioprine, cyclophosphamide, mycophenolate mofétil, cyclosporine, tacrolimus) * Corticosteroid therapy = 1mg / kg of equivalent prednisone for more than a month * Toxic shock due to a deep candidiasis in the admission in resuscitation * Congenital deficits of Th17 (cutanéo-mucous candidiasis chronicles, syndrome of hyper IgE)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Candidiasis infection occurence | Day 28 survival | Outcome |
Countries
France
Outcome results
None listed